Correlation between morphology and EGFR mutations in lung adenocarcinomas Significance of the micropapillary pattern and the hobnail cell type.

[1]  H. Sasaki,et al.  EGFR exon 20 insertion mutation in Japanese lung cancer. , 2007, Lung cancer.

[2]  J. Soh,et al.  The Impact of Sex and Smoking Status on the Mutational Spectrum of Epidermal Growth Factor Receptor Gene in Non–small Cell Lung Cancer , 2007, Clinical Cancer Research.

[3]  Y. Ishikawa,et al.  Up-regulation of PTEN at the transcriptional level is an adverse prognostic factor in female lung adenocarcinomas. , 2007, Lung cancer.

[4]  Chan Zeng,et al.  Antitumor Activity of the Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Gefitinib (ZD1839, Iressa) in Non–Small Cell Lung Cancer Cell Lines Correlates with Gene Copy Number and EGFR Mutations but not EGFR Protein Levels , 2006, Clinical Cancer Research.

[5]  Kenji Suzuki,et al.  Frequent EGFR mutations in noninvasive bronchioloalveolar carcinoma , 2006, International journal of cancer.

[6]  J. Baselga,et al.  Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Y. Ogawa,et al.  Diffuse micronodular pulmonary metastasis of lung adenocarcinoma predicts gefitinib response in association with epidermal growth factor receptor mutations. , 2006, Anticancer research.

[8]  H. Sasaki,et al.  A correlation between EGFR gene mutation status and bronchioloalveolar carcinoma features in Japanese patients with adenocarcinoma. , 2006, Japanese journal of clinical oncology.

[9]  C. Tzen,et al.  Female sex and bronchioloalveolar pathologic subtype predict EGFR mutations in non-small cell lung cancer. , 2005, Chest.

[10]  H. Iwasaki,et al.  Micropapillary pattern: a distinct pathological marker to subclassify tumours with a significantly poor prognosis within small peripheral lung adenocarcinoma (≤20 mm) with mixed bronchioloalveolar and invasive subtypes (Noguchi's type C tumours) , 2005, Histopathology.

[11]  Y. Yatabe,et al.  EGFR Mutation Is Specific for Terminal Respiratory Unit Type Adenocarcinoma , 2005, The American journal of surgical pathology.

[12]  Young Hak Kim,et al.  Dominant Papillary Subtype Is a Significant Predictor of the Response to Gefitinib in Adenocarcinoma of the Lung , 2004, Clinical Cancer Research.

[13]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[14]  Daniel Jones.  Anticancer drugs: To the rescue? , 2004, Nature Reviews Drug Discovery.

[15]  William Pao,et al.  Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  F. Cappuzzo,et al.  Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Y. Ishikawa,et al.  Early-Stage Lung Adenocarcinomas With a Micropapillary Pattern, a Distinct Pathologic Marker for a Significantly Poor Prognosis , 2003, The American journal of surgical pathology.

[18]  Jungsil Ro,et al.  Micropapillary Component in Lung Adenocarcinoma: A Distinctive Histologic Feature With Possible Prognostic Significance , 2002, The American journal of surgical pathology.

[19]  N. Rosen,et al.  The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. , 2001, Cancer research.

[20]  S. Piantadosi,et al.  Chromosomal alterations in lung adenocarcinoma from smokers and nonsmokers. , 2001, Cancer research.

[21]  J. Hayashi,et al.  Different subtypes of human lung adenocarcinoma caused by different etiological factors. Evidence from p53 mutational spectra. , 2000, The American journal of pathology.

[22]  Monilola A. Olayioye,et al.  The ErbB signaling network: receptor heterodimerization in development and cancer , 2000, The EMBO journal.

[23]  E. Mark,et al.  Bronchoalveolar carcinoma: clinical, radiologic, and pathologic factors and survival. , 1999, The Journal of thoracic and cardiovascular surgery.

[24]  A. Borczuk,et al.  Patterns of allelic loss differ in lung adenocarcinomas of smokers and nonsmokers. , 2003, Lung cancer.